Liver Fibrosis Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight's "Liver Fibrosis Pipeline Insight 2026" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Liver Fibrosis pipeline landscape. It covers the Liver Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Liver Fibrosis Pipeline? @ https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Liver Fibrosis Pipeline Report
• On July 29, 2026- AstraZeneca initiated a study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis. Approximately 230 participants with SLD and advanced fibrosis will be screened such that approximately 104 participants will be randomised. Approximately 52 participants will be randomised to receive AZD2389 and approximately 52 participants will receive placebo.
• On July 22, 2026- Boehringer Ingelheim conducted a phase IIa study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition.
• DelveInsight's Liver Fibrosis Pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Liver Fibrosis treatment.
• The leading Liver Fibrosis Companies such as Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics and others.
• Promising Liver Fibrosis Therapies such as Candesartan, Ramipril, Hydronidone, Atorvastatin 20mg, Silymarin, Ursodeoxycholic Acid, ND-L02-s0201 Injection, Sildenafil 20 MG, Sulfasalazine enteric-coated tablets and others.

Want to know which companies are leading innovation in Liver Fibrosis? Dive into the full pipeline insights @ https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Liver Fibrosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Liver Fibrosis Pipeline Report also highlights the unmet needs with respect to the Liver Fibrosis.

Liver Fibrosis Overview
Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, in the liver due to chronic injury. It is a progressive condition that results from sustained inflammation and hepatocyte damage, often caused by chronic viral hepatitis (HBV, HCV), alcohol abuse, non-alcoholic fatty liver disease (NAFLD), or autoimmune liver diseases. While early-stage fibrosis may be reversible, advanced fibrosis can progress to cirrhosis, liver failure, and hepatocellular carcinoma (HCC). The signs and symptoms of liver fibrosis are often nonspecific in the early stages, making it difficult to diagnose. Many patients remain asymptomatic until significant liver damage has occurred. As fibrosis progresses, individuals may experience fatigue, unexplained weight loss, abdominal discomfort, and mild jaundice. In more advanced stages, complications such as portal hypertension, ascites, splenomegaly, and variceal bleeding may develop.

Liver Fibrosis Emerging Drugs Profile
• Aramchol: Galmed Research and Development, Ltd
Aramchol (Arachidyl Amido Cholanoic Acid) is a first-in-class, novel synthetic small molecule, a conjugate of Cholic Acid and Arachidic Acid, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of NASH (Nonalcoholic Steatohepatitis) and fibrosis. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation, and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol, by targeting this single receptor, induces a cascade of events that leads to two main changes; in hepatocytes, Aramchol elevates the fatty acids oxidation (or in other words - fat burn) and influences AMPK, which results also in reducing glycemic parameters; and in hepatic stellate cells, Aramchol has been shown to down-regulate the expression and activity of stearoyl-CoA desaturase-1 (SCD-1), resulting in a direct effect on fibrogenesis. Currently, the drug is in the Phase III stage of its development for the treatment of Liver Fibrosis

• Belapectin: Galectin Therapeutics
Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Belapectin binds to galectin-3 and disrupts its function. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. Currently, the drug is in Phase II/III stage of development for the treatment of liver fibrosis.

• AZD2693: AstraZeneca
AZD2693 is a liver-targeted antisense oligonucleotide against PNPLA3 mRNA. AZD2693 lowers the mRNA expression of PNPLA3 in patients that are homozygotes for the 148M risk allele thereby reducing an important disease driver for NASH. AZD2693 has been evaluated in 3-month repeat dose subcutaneous toxicity study in preclinical species. Findings were consistent with typical class effects of ASOs, including histiocytic infiltration in multiple tissues and evidence of ASO accumulation in liver and spleen. No effects were attributed to the reduction in PNPLA3. Preclinical safety pharmacology studies have also been conducted with no effects on the respiratory, cardiovascular, and central and peripheral nervous systems. Under preclinical pharmacology, Murine PNPLA3 tool ASO has been shown to reduce liver steatosis, inflammation and fibrosis in homozygous PNPLA3 148M knock-in mice. Currently, the drug is in the Phase II stage of its development for the treatment of Liver Fibrosis.

• RTX001: Resolution Therapeutics
RTX001 is an engineered, autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effect. The product candidate is engineered with IL-10-MMP9 mRNA to enhance the natural regenerative properties of macrophages for superior efficacy and durability. RTX001 is an innovative medical treatment being studied for patients with decompensated liver cirrhosis. It is classified as an autologous macrophage therapy, which means it uses the patient's own immune cells to potentially treat their condition. RTX001 is administered as a dispersion for infusion, which is a liquid form of the medication that is given directly into the bloodstream through an Intravenous (IV) line. Currently, the drug is in the Phase I/II stage of its development for the treatment of Liver Fibrosis

• AD-214: AdAlta
AD-214 is AdAlta's lead drug candidate, an Fc-fusion protein that combines anti-body with the Fc fragment of a traditional monoclonal antibody to extend its duration in the body. AD-214 binds to the CXCR4 receptor on target diseased cells, exerting anti-inflammatory and anti-fibrotic effects without impacting healthy cells. It has demonstrated efficacy in animal models of fibrosis and is being explored for the treatment of liver fibrosis. Currently, the drug is in Preclinical stage of its clinical trial for the treatment of liver fibrosis.

If you're tracking ongoing Liver Fibrosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Liver Fibrosis Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Liver Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Fibrosis Treatment.
• Liver Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Liver Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Fibrosis market.

Liver Fibrosis Companies
Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics and others.

Liver Fibrosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Liver Fibrosis Products have been categorized under various Molecule types such as,
• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Liver Fibrosis Pipeline Report covers it all - check it out now @ https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Liver Fibrosis Pipeline Report
• Coverage- Global
• Liver Fibrosis Companies- Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics and others
• Liver Fibrosis Therapies- Candesartan, Ramipril, Hydronidone, Atorvastatin 20mg, Silymarin, Ursodeoxycholic Acid, ND-L02-s0201 Injection, Sildenafil 20 MG, Sulfasalazine enteric-coated tablets and others.
• Liver Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Liver Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Liver Fibrosis Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Introduction
2. Executive Summary
3. Liver Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Fibrosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Aramchol: Galmed Research and Development, Ltd
9. Mid Stage Products (Phase II)
10. Belapectin: Galectin Therapeutics
11. Early Stage Products (Phase I)
12. RTX001: Resolution Therapeutics
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Liver Fibrosis Key Companies
16. Liver Fibrosis Key Products
17. Liver Fibrosis- Unmet Needs
18. Liver Fibrosis- Market Drivers and Barriers
19. Liver Fibrosis- Future Perspectives and Conclusion
20. Liver Fibrosis Analyst Views
21. Liver Fibrosis Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.